aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
March 13, 2025 16:01 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing
March 12, 2025 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through...
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
March 12, 2025 08:00 ET
|
CG Oncology Inc.
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
March 12, 2025 02:00 ET
|
Zealand Pharma
Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with...
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
March 11, 2025 21:32 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Matteo Paz,18, of Pasadena, CA,...
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025 08:00 ET
|
Ovid Therapeutics Inc.
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move...
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
March 11, 2025 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a...
Alumis to Present at Leerink's 2025 Global Healthcare Conference
March 10, 2025 08:00 ET
|
Alumis Inc.
Alumis to Present at Leerink's 2025 Global Healthcare Conference
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
March 10, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
March 08, 2025 13:00 ET
|
Regeneron Pharmaceuticals, Inc.
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly...